Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts-Reference-Cited by-同舟云学术

Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts

Published:2020-04 Issue:4 Volume:23 Page:471-480
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Wranik Wiesława Dominika,Jakubczyk Michał,Drachal Krzysztof

Funder

European Union Horizon 2020

Canadian Institutes for Health Research

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference52 articles.

1. Health technology assessment at age 25 – squaring the circle of strong methodology and context-dependency?;Pantelli;Health Policy,2019

2. A synthesis of drug reimbursement decision-making processes in Organisation for Economic Co-Operation and Development countries;Barnieh;Value Health,2014

3. Informing Canada’s cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review;Hoch;Curr Oncol,2013

4. Pan-Canadian Oncology Drug Review (pCODR): a unique model to support harmonization of cancer drug funding decisions in Canada;Trudeau;J Clin Oncol,2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a Value Assessment Framework for Pediatric Health Technologies Using Multicriteria Decision Analysis: Expanding the Value Lens for Funding Decision Making;Value in Health;2024-07

2. How sure are you? — the properties of self-reported conviction in the elicitation of health preferences with discrete choice experiments;Theory and Decision;2023-08-01

3. Hypoxia-regulated microRNAs: the molecular drivers of tumor progression;Critical Reviews in Biochemistry and Molecular Biology;2022-07-04

4. Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions? A Discrete Choice Experiment Among Dutch Healthcare Decision Makers;Value in Health;2022-02

5. What matters in treating non‐oncological rare diseases?—Eliciting experts' preferences in Poland with PAPRIKA;Journal of Multi-Criteria Decision Analysis;2021-06-13